نتایج جستجو برای: l1 vlp

تعداد نتایج: 33233  

Journal: :Journal of immunology 2005
Rongcun Yang Francisco Martinez Murillo Michael J Delannoy R Lee Blosser William H Yutzy Satoshi Uematsu Kiyoshi Takeda Shizuo Akira Raphael P Viscidi Richard B S Roden

Vaccination with human papillomavirus type 16 (HPV16) L1 virus-like particles (VLP) induces both high titer neutralizing IgG and protective immunity. Because protection from experimental infection by papillomavirus is mediated by neutralizing IgG, we sought the mechanisms that trigger humoral immunity to HPV16 L1 VLP. We find that HPV16 L1 VLP bind to murine B lymphocytes thereby inducing activ...

Journal: :The Indian journal of medical research 2009
Mira C Patel Ketaki K Patkar Atanu Basu K M Mohandas Robin Mukhopadhyaya

BACKGROUND & OBJECTIVE Recombinant DNA technology allows expression of the human papillomavirus (HPV) major capsid protein (L1) in heterologous expression systems and the recombinant protein self assembles to virus-like particles (VLP). We took up this study to produce recombinant HPV-16 L1 in yeast, establish the process of recombinant L1 derived VLP preparation and develop an ELISA using VLP ...

Journal: :iranian journal of basic medical sciences 0
asghar abdoli department of virology, faculty of medical sciences, tarbiat modares university, tehran, iran hoorieh soleimanjahi department of virology, faculty of medical sciences, tarbiat modares university, tehran, iran fatemeh fotouhi influenza research lab, department of virology, pasteur institute of iran, tehran, iran shahram pour beiranvand department of anatomy, faculty of medical sciences, tarbiat modares university, tehran, iran zahra kianmehr influenza research lab, department of virology, pasteur institute of iran, tehran, iran

objective(s):  infection by high-risk papillomavirus is regarded as the major risk factor in the development of cervical cancer. recombinant dna technology allows expression of the l1 major capsid protein of hpv in different expression systems, which has intrinsic capacity to self-assemble into viral-like particles (vlp). vlps are non-infectious, highly immunogenic and can elicit neutralizing a...

Asghar Abdoli Fatemeh Fotouhi Hoorieh Soleimanjahi, Shahram Pour Beiranvand Zahra Kianmehr

  Objective(s):  Infection by high-risk papillomavirus is regarded as the major risk factor in the development of cervical cancer. Recombinant DNA technology allows expression of the L1 major capsid protein of HPV in different expression systems, which has intrinsic capacity to self-assemble into viral-like particles (VLP). VLPS are non-infectious, highly immunogenic and can elicit neutralizing...

2017
Bettina Huber Christina Schellenbacher Saeed Shafti-Keramat Christoph Jindra Neil Christensen Reinhard Kirnbauer

Common cutaneous human papillomavirus (HPV) types induce skin warts, whereas species beta HPV are implicated, together with UV-radiation, in the development of non-melanoma skin cancer (NMSC) in immunosuppressed patients. Licensed HPV vaccines contain virus-like particles (VLP) self-assembled from L1 major capsid proteins that provide type-restricted protection against mucosal HPV infections ca...

2014
Hilary A Robbins Yan Li Carolina Porras Michael Pawlita Arpita Ghosh Ana Cecilia Rodriguez Mark Schiffman Sholom Wacholder Troy J Kemp Paula Gonzalez John Schiller Douglas Lowy Mark Esser Katie Matys Wim Quint Leen-Jan van Doorn Rolando Herrero Ligia A Pinto Allan Hildesheim Tim Waterboer Mahboobeh Safaeian

BACKGROUND Several assays are used to measure type-specific serological responses to human papillomavirus (HPV), including the bead-based glutathione S-transferase (GST)-L1 multiplex serology assay and virus-like particle (VLP)-based ELISA. We evaluated the high-throughput GST-L1, which is increasingly used in epidemiologic research, as a measure of cumulative HPV infection and future immune pr...

Journal: :Vaccine 2004
Kevin A Ault Anna R Giuliano Robert P Edwards Gretchen Tamms Lee-Lian Kim Judith F Smith Kathrin U Jansen Maria Allende Frank J Taddeo DeeMarie Skulsky Eliav Barr

Human papillomavirus (HPV) infection can cause genital warts and cervical cancer. HPV types 6 and 11 cause >90% of genital wart cases; HPV16 and 18 cause 70% of cervical cancers. A prophylactic HPV (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine may substantially reduce the incidence of these lesions. This report describes the results of a phase I study of the HPV18 component of such...

Journal: :Journal of virology 2015
Sara L Bissett Anna Godi Maxime J J Fleury Antoine Touze Clementina Cocuzza Simon Beddows

UNLABELLED We investigated naturally occurring variation within the major (L1) and minor (L2) capsid proteins of oncogenic human papillomavirus (HPV) genotype 31 (HPV31) to determine the impact on capsid antigenicity. L1L2 pseudoviruses (PsVs) representing the three HPV31 variant lineages, variant lineages A, B, and C, exhibited comparable particle-to-infectivity ratios and morphologies. Lineag...

Journal: :Vaccine 2004
Darron R Brown Kenneth H Fife Cosette M Wheeler Laura A Koutsky Lisa M Lupinacci Radha Railkar Gretchen Suhr Eliav Barr Anthony Dicello Weili Li Judith F Smith Amha Tadesse Kathrin U Jansen

A post hoc analysis was performed using combined data from two Phase I tolerability/immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 virus-like particle (VLP) vaccines. The goal was to determine if the HPV16 L1 VLP vaccine protected against HPV16 infection. Vaccine or placebo was given at 0, 2 and 6 months. HPV16 infection was defined by positive polymerase ...

Journal: :Journal of immunology 2009
Alfonso J García-Piñeres Allan Hildesheim Lori Dodd Troy J Kemp Jun Yang Brandie Fullmer Clayton Harro Douglas R Lowy Richard A Lempicki Ligia A Pinto

Human papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed. Although neutralizing Ab titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet defined and a comprehensive understanding of innate and adaptive immune responses to vaccination is still lacking. Here, microarrays were used to compare the ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید